GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (NAS:GRFS) » Definitions » Cyclically Adjusted Revenue per Share

GRFS (Grifols) Cyclically Adjusted Revenue per Share : $6.86 (As of Dec. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Grifols Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Grifols's adjusted revenue per share for the three months ended in Dec. 2024 was $3.041. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $6.86 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Grifols's average Cyclically Adjusted Revenue Growth Rate was 8.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Grifols was 10.80% per year. The lowest was 10.20% per year. And the median was 10.50% per year.

As of today (2025-05-15), Grifols's current stock price is $7.57. Grifols's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 was $6.86. Grifols's Cyclically Adjusted PS Ratio of today is 1.10.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Grifols was 6.43. The lowest was 0.93. And the median was 2.19.


Grifols Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Grifols's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Cyclically Adjusted Revenue per Share Chart

Grifols Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.41 - 5.62 5.80 6.86

Grifols Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.66 5.80 6.48 7.08 6.86

Competitive Comparison of Grifols's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, Grifols's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grifols's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Grifols's Cyclically Adjusted PS Ratio falls into.


;
;

Grifols Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Grifols's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=3.041/124.7533*124.7533
=3.041

Current CPI (Dec. 2024) = 124.7533.

Grifols Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 1.597 100.139 1.990
201406 1.595 101.081 1.969
201409 1.541 100.441 1.914
201412 1.647 100.251 2.050
201503 1.454 99.474 1.824
201506 1.591 101.138 1.962
201509 1.556 99.559 1.950
201512 1.669 100.268 2.077
201603 1.535 98.638 1.941
201606 1.603 100.333 1.993
201609 1.664 99.737 2.081
201612 1.696 101.842 2.078
201703 1.662 100.896 2.055
201706 1.855 101.848 2.272
201709 1.799 101.524 2.211
201712 1.850 102.975 2.241
201803 1.845 102.122 2.254
201806 1.898 104.165 2.273
201809 1.966 103.818 2.362
201812 1.980 104.193 2.371
201903 1.943 103.488 2.342
201906 2.074 104.612 2.473
201909 2.116 103.905 2.541
201912 2.186 105.015 2.597
202003 2.089 103.469 2.519
202006 2.445 104.254 2.926
202009 2.317 103.521 2.792
202012 2.309 104.456 2.758
202103 2.064 104.857 2.456
202106 2.380 107.102 2.772
202112 0.000 111.298 0.000
202206 2.402 118.044 2.539
202209 2.248 117.221 2.392
202212 2.674 117.650 2.835
202306 2.833 120.278 2.938
202309 2.511 121.343 2.582
202312 2.842 121.300 2.923
202406 2.637 124.409 2.644
202409 2.928 123.121 2.967
202412 3.041 124.753 3.041

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Grifols  (NAS:GRFS) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Grifols's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=7.57/6.86
=1.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Grifols was 6.43. The lowest was 0.93. And the median was 2.19.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Grifols Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Grifols's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Grifols Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (NAS:GRFS) » Definitions » Cyclically Adjusted Revenue per Share
Address
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.